STUDIES OF THE INDUCTION AND MAINTENANCE OF LONG-TERM GRAFT ACCEPTANCE BY TREATMENT WITH FK506 IN HETEROTOPIC CARDIAC ALLOTRANSPLANTATION IN RATS
- 1 December 1987
- journal article
- research article
- Published by Wolters Kluwer Health in Transplantation
- Vol. 44 (6) , 734-738
- https://doi.org/10.1097/00007890-198712000-00002
Abstract
Immunosuppressive activities of the newly discovered FK506, isolated from Streptomyces tsukubaensis, were examined by using cardiac allotransplantation in the rat, and the mechanisms underlying induction and maintenance of FK506-induced long-term allograft survival were studied. Male rats of WKA (RT1k) and F344 (RT1Iv1) strains were used as recipients and donors, respectively, and those of BN (RT1n) strain were used as third-party donors. Treatment with FK506, beginning from the day of allografting for 14, 10, or as few as 4 days, prolonged allograft survival significantly across the major histocompatibility barrier. The minimum doses for prolonging graft survival were 0.1 mg/kg/day by intramuscular treatment and 1.0 mg/kg/day by oral treatment. Treatment with FK506 at a dose of 0.32 mg/kg/day from day 4 until day 10 resulted in all the grafts surviving indefinitely and from days 5 to 10, half the grafts survived indefinitely, suggesting that the agent inhibited ongoing rejection. On the other hand, cyclosporine treatment at a dose of 20 mg/kg/day from day 2 did not prolong graft survival time statistically significantly. Induction of prolonged graft survival was not obtained by pretreatment of the prospective donor or recipient; prolonging effects were observed only when the agent was administered after allografting. Thus, the primary effect of the agent is exerted on responder lymphocytes reacting to the donor antigens in the induction phase of long-term graft acceptance. The mechanisms underlying the maintenance of long-term grafts were analyzed by testing the capacity of lymphocytes or serum of long-term graft-bearing rats to inhibit graft rejection in irradiated grafted hosts. Transfer of 2×108 lymphocytes from FK506-induced long-term F344 graft-bearing WKA rats resulted in indefinite survival of F344 heart allografts, but it did not prolong survival of third-party BN hearts. Transfer of 2.5 ml serum from long-term graft-bearing rats also prolonged graft survival of F344 hearts, but not BN hearts. These results suggest that donor strain–specific suppressor cells and humoral factor(s) are induced by treatment with FK506 in the presence of allografts, and that they play at least partial roles in the maintenance of long-term allograft acceptance.This publication has 8 references indexed in Scilit:
- FK-506, a novel immunosuppressant isolated from a Streptomyces. II. Immunosuppressive effect of FK-506 in vitro.The Journal of Antibiotics, 1987
- EFFECT OF INTERLEUKIN 2 ON THE IMMUNOSUPPRESSIVE ACTION OF CYCLOSPORINETransplantation, 1985
- ROLE OF IA-POSITIVE CELLS IN THE BENEFICIAL EFFECT OF DONOR BLOOD TRANSFUSION AND INDUCTION OF SUPPRESSOR CELLS IN CARDIAC ALLOTRANSPLANTATION OF RATSTransplantation, 1984
- SUPPRESSOR T CELLS IN RATS WITH PROLONGED CARDIAC ALLOGRAFT SURVIVAL AFTER TREATMENT WITH CYCLOSPORINE1Transplantation, 1984
- ENFORCEMENT OF SPECIFIC UNRESPONSIVENESS BY THE LONG-TERM PRESENCE OF ALLOGENEIC HEART GRAFTSTransplantation, 1984
- Restoration of immunogenicity to passenger cell-depleted kidney allografts by the addition of donor strain dendritic cells.The Journal of Experimental Medicine, 1982
- CYCLOSPORIN A SPARES SELECTIVELY LYMPHOCYTES WITH DONOR-SPECIFIC SUPPRESSOR CHARACTERISTICSTransplantation, 1981
- Cyclosporin A mediates immunosuppression of primary cytotoxic T cell responses by impairing the release of interleukin 1 and interleukin 2European Journal of Immunology, 1981